<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00440362</url>
  </required_header>
  <id_info>
    <org_study_id>AVX502-002</org_study_id>
    <nct_id>NCT00440362</nct_id>
  </id_info>
  <brief_title>A Phase 1/2 Clinical Trial of an Alphavirus Replicon Vaccine for Influenza</brief_title>
  <official_title>A Single-Site, Phase 1/2, Double-Blind, Safety and Immunogenicity Trial of an Alphavirus Replicon Vaccine Expressing Influenza A/Wyoming/03/2003 Hemagglutinin (AVX502) in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AlphaVax, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AlphaVax, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      AVX502, an alphavirus replicon vaccine expressing an influenza HA protein, is a candidate
      vaccine against influenza.

      The objectives of this Phase 1 study are to test the safety of the vaccine and the immune
      response to the vaccine in healthy volunteers 18-40 years of age. Volunteers will be assigned
      by randomization to receive either the vaccine or an inactive substance (placebo) by
      injections in each arm on one or two occasions over 2 months. The study will last 4 months
      and will have a total of 8 visits.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled Phase 1/2 study of the safety and
      immunogenicity of AVX502 vaccine at two dosage levels and two routes of administration in
      healthy volunteers conducted at a single research center. A total of 216 participants will be
      enrolled. Participants will be randomized to receive active vaccine at one of two dosage
      levels or placebo in a 4:4:1 ratio. Within each active dosage level or placebo subgroup,
      participants will be randomized to receive their injections by either IM or SC injection in a
      1:1 ratio, and will also be randomized to receive either 1 injection (at Week 0) or 2
      injections (1 at each of two visits at Weeks 0 and 8) in a 1:1 ratio. Vaccine will be
      administered by a study nurse in an outpatient setting and all participants will be followed
      for 4 months after the first immunization. Safety data will include local and systemic
      reactogenicity after each dose of vaccine, collected in a systematic format using a subject
      memory aid and a standard grading scale, specific safety laboratory parameters and general
      AEs. Immunogenicity data will be obtained by collecting blood at defined time points before
      and after immunization and separating serum (for measurement of antibodies to HA by ELISA and
      hemagglutination inhibition assays and to the vaccine vector by a VRP neutralization assay)
      and peripheral blood mononuclear cells (PMBC) (for measurement of cellular immune responses
      to HA peptides).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate safety of AVX502 in healthy volunteers via frequency of Grade 2-4 systemic reactogenicity events, grade 3 or 4 local vaccine reactions and all AE's</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate immunogenicity of AVX502 in healthy volunteers via serum antibody concentration</measure>
    <time_frame>4 weeks post first dose of vaccine</time_frame>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">216</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>T1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>T2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>T3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>T4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>T5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>T6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>T7</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>T8</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AVX502</intervention_name>
    <description>1 dose at 2e8 IU given at t=0 via IM route</description>
    <arm_group_label>T2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AVX502</intervention_name>
    <description>1 dose at 2e7 IU given at T=0 via the IM route</description>
    <arm_group_label>T1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AVX502</intervention_name>
    <description>1 dose at 2e7 IU given at t=0 via the SC route</description>
    <arm_group_label>T3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AVX502</intervention_name>
    <description>1 dose at 2e8 IU given at T=0 via the SC route</description>
    <arm_group_label>T4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AVX502</intervention_name>
    <description>2 doses at 2e7 IU given at T=0 and 8 weeks via the IM route</description>
    <arm_group_label>T5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AVX502</intervention_name>
    <description>2 doses at 2e8 IU given at T=0 and 8 weeks via the IM route</description>
    <arm_group_label>T6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AVX502</intervention_name>
    <description>2 doses of 2e7 IU given at t=0 and 8 weeks via the SC route</description>
    <arm_group_label>T7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AVX502</intervention_name>
    <description>2 doses at 2e8 IU given at T=0 and 8 weeks via the SC route</description>
    <arm_group_label>T8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 dose of placebo given at T=0 via the IM route</description>
    <arm_group_label>C1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 dose of placebo given at T=0 via the SC route</description>
    <arm_group_label>C2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 doses of placebo given at T=0 and 8 weeks via the IM route</description>
    <arm_group_label>C3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 doses of placebo given at T=0 and 8 weeks via the SC route</description>
    <arm_group_label>C4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Between 18 and 40 years of age, inclusive;

          2. Good general health without significant physical examination findings or clinically
             significant abnormal laboratory results;

          3. Available to participate for the entire study period of approximately 4 months;

          4. For women of childbearing potential, a negative urine pregnancy test at screening and
             before each immunization, and agreement to consistently use contraception from 28 days
             prior to enrollment until the last protocol visit, for sexual activity that could lead
             to pregnancy;

          5. Acceptable laboratory parameters: hemoglobin ≥ 11.2 g/dL for women, ≥ 12.8 g/dL for
             men, white blood cell count 3,300 - 12,000 cells/mm3, platelet count 125,000 -
             550,000/mm3, alanine aminotransferase (ALT) within normal range for study laboratory,
             serum creatinine within normal range for study laboratory, normal urine dipstick
             (negative glucose, negative hemoglobin, and negative or trace protein), negative
             hepatitis B virus (HBV) and hepatitis C virus (HCV) blood tests, negative HIV blood
             test;

          6. Willingness to have blood stored for up to 10 years for use in additional assays to
             evaluate immune responses to influenza or the alphavirus vector if such assays become
             available

          7. Willingness to participate in the study as evidenced by signed informed consent
             obtained before screening.

        Exclusion Criteria:

          1. Venous access deemed inadequate for the phlebotomy demands of the study;

          2. Women who are breast feeding;

          3. In female subjects, a positive urine pregnancy test at screening or on the day of any
             vaccine injection;

          4. Receipt of any influenza vaccine within 12 months prior to enrollment;

          5. Receipt of any other vaccine within 30 days prior to enrollment;

          6. Use of any investigational agent within 30 days prior to enrollment;

          7. Receipt of immunoglobulin or blood products within 60 days prior to enrollment;

          8. Use of cytotoxic medications within 6 months prior to enrollment;

          9. Use of systemic corticosteroids within 6 months prior to enrollment (except that
             participants who have completed a course of prednisone, at up to 20 mg per day for up
             to 7 days, at least 1 month prior to enrollment are eligible for enrollment);

         10. Presence of any factor that places the individual at increased risk for severe
             complications from influenza;

         11. History of serious adverse reactions to any vaccine, including anaphylaxis and related
             symptoms such as hives, respiratory difficulty, angioedema or abdominal pain;

         12. History of autoimmune disease;

         13. History of splenectomy;

         14. History of malignancy within the last 3 years (except that participants with a
             diagnosis of basal cell carcinoma of the skin are eligible for enrollment);

         15. Psychiatric condition that may interfere with the ability to comply with the protocol
             requirements. Specifically excluded are persons with history of psychosis within the
             past 3 years or history of suicidal attempt or gesture within the past 3 years;

         16. History of medical, occupational or family problems as a result of alcohol or illicit
             drug use during the past 12 months;

         17. Any condition which leads the investigator to believe that the participant cannot
             comply with the protocol requirements or that may place the participant at an
             unacceptable risk for participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert A Olmsted, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>AlphaVax, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johnson County Clin-Trials</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.alphavax.com</url>
    <description>AlphaVax, Inc.</description>
  </link>
  <link>
    <url>http://www.jococt.com</url>
    <description>Johnson County Clin-Trials</description>
  </link>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2007</study_first_submitted>
  <study_first_submitted_qc>February 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2007</study_first_posted>
  <last_update_submitted>November 7, 2008</last_update_submitted>
  <last_update_submitted_qc>November 7, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2008</last_update_posted>
  <responsible_party>
    <name_title>Robert Olmsted, Ph.D.</name_title>
    <organization>AlphaVax, Inc.</organization>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Flu</keyword>
  <keyword>A/Wyoming/03/2003</keyword>
  <keyword>Alphavirus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

